Go to virtual 3D site

Press Release from HUB Organoids

Profile

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer.

First Clinical Candidate Developed using HUB Organoids® and High Content Screening Targets Cancer Stem Cells in Solid Tumors, Published in Nature Cancer. San Diego, California, April 28, 2022 – HUB Organoids (HUB) and Crown Bioscience, a JSR Life Sciences company, announced today the publication of preclinical data in the journal, Nature Cancer, on a bispecific antibody which prevents the onset of metastasis and slows the growth of primary tumors in experimental models of cancer.

The study was the result of work by an international consortium, SuppresSTEM which included Crown Bioscience (previously OcellO B.V.) and HUB. Crown Bioscience and HUB led the design of the experiments which were executed using the high content screening platform from Crown Bioscience using HUB Organoids. These studies enabled the discrimination of antibodies that were active against a broad range of mutational profiles and tumor subtypes, with hit validation and mechanism of action studies that enabled selection of optimally performing antibodies. Follow up in vivo studies in matched patient-derived xenograft (PDX) models were also performed by Crown Bioscience.

The work, spanning about five years, involved Crown Bioscience screening a library of hundreds of bispecific antibodies and rescreening of ‘hits’ in a panel of patient-derived colorectal cancer organoids and matching normal organoids, that were developed by HUB and characterized by HUB and other consortium members. Organoids are stem cell-derived mini-organs developed from any patient resection or biopsy tissue that can be grown in the laboratory, which can be applied like conventional cell lines in early drug discovery.

“This is the first study that has used organoids exclusively for cell-based compound screening and characterization, leading to a compound entering clinical trials. This is a truly remarkable achievement that demonstrates the validity and application of HUB Organoids in high throughput screening and oncology drug discovery”, said Leo Price PhD, Senior Vice President In Vitro Oncology at Crown Bioscience.

“This groundbreaking work demonstrates the power and potential of HUB Organoid Technology”, commented Rob Vries PhD, CEO at HUB. “Using organoids, we were able to accelerate the timeline from initial discovery to clinical trials to about five years.”

Nature Cancer is a journal which covers the latest, most significant cancer-related advances across the life, physical, applied and social sciences, focusing on new approaches for the development and delivery of diagnostics and therapeutics, as well as clinical studies regarding cancer diagnosis, treatment and prevention.

Posted: 7-Sep-2022

HUB Organoids
Netherlands
+31 88 123 6300 Main
bd@huborganoids.nl Email
Yalelaan 62
https://www.huborganoids.nl/ website
Eventflo Home
copyright ELRIG, eventflo.co.uk, Labhoo Ltd 2003-2022